Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ISP, Vivimed Labs Forge Manufacturing Alliance
The manufacturing alliance is expected to allow ISP and Vivimed to jointly market specific products used in sprays and lotions that include UVA and UVB protective properties. Under
The manufacturing alliance is expected to allow ISP and Vivimed to jointly market specific products used in sprays and lotions that include UVA and UVB protective properties. Under
HypoTech said the solution contains no toxins and is durable with a solid shelf life of two years. It has no harmful irritants or chemicals, and strong enough
Biocius and BlueSky said that the collaboration builds on an existing partnership and will improve drug discovery efficiency of the SIRT class of epigenetic modulating enzymes, which are
As per the agreement terms, Icon and Parexel are expected to provide support for Bristol-Myers Squibb’s clinical studies to support its full development pipeline over the next three
Pfizer’s ‘Rare Disease Research Unit’ is expected to pursue treatments across all therapeutic areas and modalities and will serve as the focal point for the company’s existing research
GSK said that the FDA approval for the combination was based on the results from a two-year study CombAT (Combination of Avodart and Tamsulosin), an international multicenter, randomised,
Genzyme said that under fast track designation, Alemtuzumab for MS is eligible for priority review and the FDA may consider for review portions of the marketing application before
Capsugel claimed that its France facility Ploermel provides clinical trial and commercial pharmaceutical product manufacturing services to customers around the world. The FDA’s Pre-Approval and Good Manufacturing Practices
UCB said that Vimpat is available in three formulations, oral tablets, oral solution and IV injection, ensuring that patients can maintain consistent Vimpat treatment in any clinical setting.
BioSeek and Asterand said that the recent collaboration is a follow up agreement between both the companies for peptide screening and related drug discovery activities. As per the